Roche Diabetes Care Introduces Blood Glucose Meter and Savings Program Designed to Help the Over 29 Million People Living with Diabetes
New Accu-Chek® Guide Meter Simplifies Blood Sugar Testing and SimplePay Savings Program Provides a More Affordable Option for Test Strips
Roche Diabetes Care, today announced the launch of the Accu-Chek® Guide System, a new blood glucose meter and SimplePay savings program designed to help make managing diabetes surprisingly simple and more affordable for the over 29 million Americans living with diabetes who are navigating this complex and expensive condition every day. In fact, a recent survey of 500 U.S. adults with diabetes revealed that 62 percent of those surveyed would better manage their diabetes if supplies were more affordable and 58 percent admitted to cutting corners to save money. In addition, more than half felt uncertain of the out-of-pocket cost of their test strips and were frustrated about the overall cost of managing the condition. With the introduction of the new Accu-Chek Guide SimplePay program, Roche Diabetes Care can now offer people with diabetes a solution that addresses today’s increasing insurance costs and high deductibles by offering patients to pay a consistent, and easy to understand everyday low price for test strips.
Beyond the benefits of the new savings program, the Accu-Chek Guide meter will help patients simplify the most frequent tasks needed to manage their diabetes with added features such as a new spill-resistant SmartPackTM vial that lets patients take just one strip and spill none; a larger blood application area on the strip that lets patients place a small drop of blood anywhere along the end instead of on a tiny spot; and a strip port light for testing in daytime, nighttime or anytime. Furthermore, the meter is comprised of advanced 10/10 accuracy1 for reliable results patients can trust.
“Living with diabetes can be challenging and complicated which is why we are excited to launch the new Accu-Chek Guide System combining simple advancements and state-of-the-art technology to provide a better testing experience,” said Brad Moore, Head of Roche Diabetes Care, North America. “Additionally, as a company that operates and manufactures its test strips in the US, we recognize that in addressing the needs of the millions of people in this country living with diabetes, it is equally important to provide a solution that ensures all patients receive better quality of care without cost being a barrier.”
The Accu-Chek Guide System, which is now available at most pharmacies, also automatically tracks results to the Accu-Chek® Connect diabetes management app and online portal eliminating the need for a logbook as well as a test strip ejector button, allowing fast, easy, and hygienic strip disposal.
To utilize the savings program patients can hand the SimplePay card to their pharmacist along with the Accu-Chek Guide meter and strip prescription to start saving. For more information and to download the free SimplePay Savings card visit accu-chek.com/guide.
Survey Methodology
The Roche Diabetes Care Survey was conducted by Wakefield Research (www.wakefieldresearch.com) among 500 U.S. adults with diabetes, between April 11th and April 19th, 2017, using an email invitation and an online survey.
Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results. For the interviews conducted in this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 4.4 percentage points from the result that would be obtained if interviews had been conducted with all persons in the universe represented by the sample.
About Accu-Chek® Guide
The Accu-Chek® Guide system is Roche Diabetes Care’s new generation of wireless blood glucose monitoring (BGM) systems, designed to respond to previously unmet needs of people with diabetes and their healthcare professionals. As such, it offers new features such as the exclusive, SmartPackTM spill-resistant strip vial and new test strip chemistry and design. Moreover, the system provides Bluetooth® low energy connectivity to the Accu-Chek® Connect diabetes management app and online portal and offers reliable test results that exceed the new global ISO 15197:2013/EN ISO 15197:2015 accuracy standards2,3.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek® brand has been dedicated to enabling people with diabetes to live life as normally and actively as possible as well as to empowering healthcare professionals to manage their patients’ condition in an optimal way. Today, the Accu-Chek® portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management, spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek® brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome. For more information please visit www.accu-chek.com.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For more information please contact:
Anne Gill
Head of Communications, Diabetes Care North America
Indianapolis, IN
Phone: 317.521.0500
[email protected]